Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1264 • ACR Convergence 2023
Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study
Martina Skacelova¹, Ondrej Janca², Milos Kudelka², Bishu Shrestha³, Pavel Horak⁴ and Eva Kriegova³, ¹Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, ²Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic, ³Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Olomouc, Czech Republic, ⁴Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…
Abstract Number: 1280 • ACR Convergence 2023
Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Gary Kunkel⁵, Bryce Binstadt⁶, Amy Joseph⁷, K Wysham⁸, Aleksander Lenert⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee¹, Geoffrey Thiele¹, Ted R Mikuls¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Minnesota, Minneapolis, MN, ⁷Washington University / St. Louis VA, St. Louis, MO, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Iowa, Iowa City, IA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹University of Texas Southwestern Medical Center, Dallas, TX, ¹²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The risk of aortic stenosis is increased in people with RA and valvular heart disease (VHD) is among the most over-represented causes of cardiovascular…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung¹, Chang-Hee Suh² and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, South Korea, ²Ajou University Hospital, Suwon, South Korea
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…
Abstract Number: 1329 • ACR Convergence 2023
R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Yan Chen¹, Sothy Yi¹, Vadim Markovtsov¹, Bhushan Samant¹, Andrew Chow¹, Esteban Masuda¹ and Simon Shaw², ¹Rigel Pharmaceuticals, Inc, South San Francisco, CA, ²Rigel Pharmaceuticals, Inc., South San Francisco, CA
Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1675 • ACR Convergence 2023
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei², Chi-Fang Wu², Hui Zhao², Suja Rajan³, Heather Lin² and Sharon Giordano², ¹MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas School of Public Health, Houston, TX
Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
Abstract Number: 1730 • ACR Convergence 2023
Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients
Rachel AUDO¹, Jérome Thireau², Louis Rauzier³, Marie Barozet¹, JACQUES MOREL⁴, Patrice Bideaux³, alain Lacampagne² and Claire Daien⁵, ¹CHU Montpellier, Montpellier, France, ²PhyMedExp INSERM U1046, Montpellier, France, ³PhyMedExp U1046, Montpellier, France, ⁴Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁵University Hospital, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1762 • ACR Convergence 2023
Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls
JING SONG¹, Cliff Rims¹, Matthew Dufort¹, Peter Linsley¹, Eddie James² and Jane Buckner², ¹Benaroya Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
Abstract Number: 1828 • ACR Convergence 2023
Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
Theodore Pincus¹, Rahel Hunter¹ and Nicholas Rodwell², ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia
Background/Purpose: DAS28 (disease activity score 28) and CDAI (clinical disease activity index) are prominent indices to assess patients with rheumatoid arthritis (RA) quantitatively, for which…
Abstract Number: 1910 • ACR Convergence 2023
Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice
Catherine Nasrallah¹, Lindsay Jacobsohn¹, Gabriela Schmajuk², Emma Kersey¹, Cammie Young³, Cammie Young³, Janell Martin⁴, Lori Barber⁵, Jennifer Barton⁶, Puneet Bajaj⁷, Christie M. Bartels⁸, Sancia Ferguson⁹, Elizabeth Wahl¹⁰, Kimberly DeQuattro¹¹, Patti Katz¹², Maria I. ("Maio") Danila¹³, Meera Subash¹⁴, Christina Downey¹⁵, JoAnn Zell¹⁶, Kimberly Reiter¹⁷, Elena Weinstein¹⁸ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco, Oakland, CA, ⁴American College of Rheumatology, Atlanta, GA, ⁵ACR, Atlanta, GA, ⁶VA Portland Health Care System/OHSU, Portland, OR, ⁷UT Southwestern Medical Center, Dallas, TX, ⁸University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁹University of Wisconsin, Madison, WI, ¹⁰VA Puget Sound Healthcare System, Seattle, WA, ¹¹University of Pennsylvania, Media, PA, ¹²University of California San Francisco, San Rafael, CA, ¹³University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁴University of Texas Health Science Center at Houston, Houston, TX, ¹⁵Loma Linda University Medical Center, Loma Linda, CA, ¹⁶University of Colorado Anschutz Medical Campus, Denver, CO, ¹⁷Albuquerque VA Medical Center, Albuquerque, NM, ¹⁸University of Colorado, Englewood, CO
Background/Purpose: Despite significant interest in the scale and spread of rheumatoid arthritis (RA) outcome measures to facilitate a patient-centered, treat-to-target approach, use of these measures…
Abstract Number: 2099 • ACR Convergence 2023
Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan
Tetsuji Sawada¹, Susumu Nishiyama², Shigemoto Igari¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Previous studies have highlighted the influence of pain, functional impairment, and affected joint distribution on the discordance in the global assessment of disease activity…
Abstract Number: 2116 • ACR Convergence 2023
Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Hyungjin Kim¹, Yeonghee Eun², Seonyoung Kang³, Jaejoon Lee³, Hoon-Suk Cha³, Jong Ho Cho⁴, Kwangmo Yang⁴, Kyungdo Han⁵ and Dong Wook Shin⁶, ¹Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, ⁶Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…
Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Claire Daien¹, Vera Georgescu², Guillaume Decarriere³, Gael Mouterde³, Cedric Lukas⁴, Gregoire Mercier² and JACQUES MOREL⁵, ¹University Hospital, Montpellier, France, ²Department of Medical Information, Montpellier, France, ³Rheumatology, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].